AIM To investigate the effects of t ot al flavones metasequosia (TFM) on ischemia reperfusion injury in guinea pig work ing heart. METHODS Ischemia reperfusion injury model was used to evaluate the effects of TFM. Myocardial func tion, the content of CK、LDH and the activity of MDA were measured. RESU LT TFM improved the cardiac function, decreased the release of LDH and CK and inhibited the increase of MDA content. CONCLUSION TFM had a protective effect on ischemia reperfusion injury of myocardium which could be re lated to its inhibitory effect on lipid peroxidation.

AIM To study the protective effects of total flavones metasequosia(TFM) on experimental acute myocardial infarction (AMI) in anaesthetized dogs. METHODS The parameters of coronary circulation and myocardial oxygen consumption, the degree and range of myocardial ischemia, myocardial infarct size, the activity of serum CK,LDH and the content of FFA were determined by using the AMI model of ligature of LAD in the anaesthetized open-chest dogs. RESULTS In dogs treated with TFM(in a dosage of 25, 100 mg?kg -1 , id), the myocardial oxygen consumption, degree and range of myocardial ischemia, myocardial infarct size, the activity of serum CK,LDH and the content of FFA were decreased. At the same time, myocardial blood flow was increased and coronary vascular resistance decreased significantly. CONCLUSION TFM possesses a protective effect on myocardial ischemia by modifying dysfunction of FFA, decreasing myocardial oxygen consumption and increasing myocardial blood supply.-

ObjectiveTo investigate the association of Modified Response Evaluation Criteria in Solid Tumors (mRECIST) response with the prognosis of patients with unresectable hepatocellular carcinoma (HCC) after transarterial embolization (TACE). MethodsA retrospective analysis was performed for the clinical data of 190 patients with unresectable HCC who were consecutively admitted to Department of Liver Disease and Digestive Interventional Radiology, The First Affiliated Hospital of Air Force Medical University, and treated with TACE from January 2010 to December 2014. The mRECIST criteria were used to evaluate imaging response after TACE; the patients with complete response (CR) or partial response (PR) were enrolled as response group(n=89), and those with progressive disease (PD) or stable disease (SD) were enrolled as non-response group(n=101). The Kaplan-Meier method was used to calculate median survival time, and the log-rank test was used for comparison between groups; the Cox regression model was used to identify the influencing factors for prognosis. ResultsAccording to the mRECIST criteria, 39 patients (20.5%) achieved CR, 50 (26.3%) achieved PR, 67 (35.3%) had SD, and 34 (17.9%) had PD. The objective response rate based on mRECIST was 46.8% for the whole population. The response group had a significantly longer survival time than the non-response group, and the median survival time was 29.9 (95% confidence interval ［CI］: 25.0-34.8) months for the response group and 7.5 (95% CI: 5.7-9.3) months for the non-response group (P＜0.001). The multivariate analysis showed that mRECIST response (hazard ratio ［HR］=2.02, P＜0.001), hepatitis B (HR=4.03, P＜0.001), and portal invasion (HR=2.12, P=0.008) were independent risk factors for survival. ConclusionThe mRECIST response has a certain value in predicting the prognosis of patients with unresectable HCC after TACE.